Latha Vairavan Biography and Net Worth

Latha Vairavan was promoted to chief financial officer in May 2025 and is responsible for overseeing and managing all financial operations for Arcutis. She has over 20 years of finance and accounting professional experience in the biotech industry. She joined Arcutis in 2020 and has held roles of increasing responsibility within the organization, beginning as executive director, financial planning and analysis. Most recently, she served as vice president, finance and corporate controller, where she oversaw daily accounting operations, ensured compliance with financial, accounting, and income tax regulations, led all investor relations activities, and managed financial planning and analysis. Prior to Arcutis, Ms Vairavan spent 12 years at Amgen, where she held a variety of roles of increasing responsibility within the finance organization. She ultimately served as finance director for US value and access. Ms Vairavan began her career as a financial consultant with KPMG and Arthur Andersen. She holds a bachelors of science in business administration, finance, from the University of Southern California, and is a licensed CPA in California.

What is Latha Vairavan's net worth?: The estimated net worth of Latha Vairavan is at least $2.02 million as of November 3rd, 2025. Vairavan owns 64,927 shares of Arcutis Biotherapeutics stock worth more than $2,023,125 as of December 5th. This net worth estimate does not reflect any other investments that Vairavan may own. Learn More about Latha Vairavan's net worth.
How do I contact Latha Vairavan?: The corporate mailing address for Vairavan and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Latha Vairavan's contact information.
Has Latha Vairavan been buying or selling shares of Arcutis Biotherapeutics?: During the last quarter, Latha Vairavan has sold $2,175.36 in shares of Arcutis Biotherapeutics stock. Most recently, Latha Vairavan sold 88 shares of the business's stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $24.72, for a transaction totalling $2,175.36. Following the completion of the sale, the chief financial officer now directly owns 64,927 shares of the company's stock, valued at $1,604,995.44. Learn More on Latha Vairavan's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Patrick Heron (Director), Neha Krishnamohan (Director), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Latha Vairavan (CFO), Todd Watanabe (Insider), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 4 times. They purchased a total of 7,434 shares worth more than $99,276.66. During the last year, insiders at the sold shares 50 times. They sold a total of 552,442 shares worth more than $11,637,612.79. The most recent insider tranaction occured on December, 1st when insider Masaru Matsuda sold 1,657 shares worth more than $50,091.11. Insiders at Arcutis Biotherapeutics own 9.4% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 12/1/2025.

Latha Vairavan Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/3/2025	Sell	88	$24.72	$2,175.36	64,927
8/4/2025	Sell	89	$14.33	$1,275.37	65,015

Latha Vairavan Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $31.16

$29.37

$31.39

50 Day Range

MA: $23.98

$17.57

$31.16

2 Week Range

Now: $31.16

$11.13

$31.39

Volume

2,040,243 shs

Average Volume

2,426,352 shs

Market Capitalization

$3.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69